CTOs on the Move


 
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kapost.com
  • 1800 Broadway Suite 180
    Boulder, CO USA 80302
  • Phone: 720.408.0222

Executives

Name Title Contact Details

Funding

Kapost raised $10M on 05/13/2015

Similar Companies

eLuma

eLuma is the premier provider of live, online speech therapy, OT, PT, school psychology & mental health for K-12 schools and districts across the U.S.

Intratem

Intratem is a company that provides a performance-based Enterprise Mobility Management (EMM) service, helping save businesses an average of 25% off their monthly wireless carrier expenses through Wireless Expense Management (WEM).

Alariss

Alariss is a US business expansion platform that takes care of all your needs from hiring salespeople to US compliance.

RandD Logic

R&D Logic is a San Mateo, CA-based company in the Software and Internet sector.

Ink Innovation

Ink Innovation is a provider of a unique ecosystem of blockchain, biometrics, mobile and cloud systems for the travel industry and other organizations to improve operational flow and transform passengers’ experiences and journeys worldwide.